SUVENPHAR Stock Overview
Operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Suven Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,274.45 |
| 52 Week High | ₹1,353.95 |
| 52 Week Low | ₹585.20 |
| Beta | 1.34 |
| 11 Month Change | 1.44% |
| 3 Month Change | 18.98% |
| 1 Year Change | 107.55% |
| 33 Year Change | 149.57% |
| 5 Year Change | n/a |
| Change since IPO | 656.24% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Dec 15
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)
Aug 03Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
May 12Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected
Mar 26Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching
Mar 07These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Nov 30Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?
Sep 03Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly
Aug 04Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report
Jun 11With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting
Apr 13Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
Mar 08Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?
Feb 08Shareholder Returns
| SUVENPHAR | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.02% | -0.2% | 0.3% |
| 1Y | 107.5% | 40.5% | 27.3% |
Return vs Industry: SUVENPHAR exceeded the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: SUVENPHAR exceeded the Indian Market which returned 27.3% over the past year.
Price Volatility
| SUVENPHAR volatility | |
|---|---|
| SUVENPHAR Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: SUVENPHAR has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SUVENPHAR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Sudhir Singh | suvenpharm.com |
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India.
Suven Pharmaceuticals Limited Fundamentals Summary
| SUVENPHAR fundamental statistics | |
|---|---|
| Market cap | ₹325.73b |
| Earnings (TTM) | ₹2.43b |
| Revenue (TTM) | ₹9.61b |
133.4x
P/E Ratio33.8x
P/S RatioIs SUVENPHAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUVENPHAR income statement (TTM) | |
|---|---|
| Revenue | ₹9.61b |
| Cost of Revenue | ₹4.07b |
| Gross Profit | ₹5.54b |
| Other Expenses | ₹3.11b |
| Earnings | ₹2.43b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.55 |
| Gross Margin | 57.65% |
| Net Profit Margin | 25.29% |
| Debt/Equity Ratio | 0.4% |
How did SUVENPHAR perform over the long term?
See historical performance and comparison